SuppreMol raises €15.7 million in series B financing
This article was originally published in Scrip
SuppreMol of Germany has closed a €15.7 million series B financing round. The lead investors were MIG and BioMedInvest. Santo Holding and the existing investors Zetacube, KfW Mittelstandsbank, Bayern Kapital and Max-Planck-Gesellschaft also participated. SuppreMol is developing novel therapeutics for the treatment of autoimmune diseases. The proceeds of the round will be used to advance its lead product
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.